Table 7. Clinicopathological features of 48 relapsed patients vs. 75 relapse-free patients.
| Items | Number of patients | ||
|---|---|---|---|
| 48 cases | 75 cases | P value | |
| Menopause | |||
| Yes | 23 (47.9%) | 33 (44%) | 0.713 |
| No | 25 (52.1%) | 42 (56%) | |
| Tumor size (cm) | |||
| T1 (T≤2) | 12 (25%) | 29 (38.7%) | 0.004 |
| T2 (2<T≤5) | 20 (41.7%) | 39 (52.0%) | |
| T3 or lager (T>5) | 16 (33.3%) | 7 (9.3%) | |
| Lymph node involvement | |||
| N0 | 15 (31.3%) | 35 (46.7%) | 0.052 |
| N1 | 10 (20.8%) | 23 (30.7%) | |
| N2 | 23 (47.9%) | 17 (22.7%) | |
| Tumor grade | |||
| 2 | 14 (29.2%) | 23 (30.7%) | 0.86 |
| 3 | 34 (70.8%) | 52 (69.3%) | |
| Hormone receptor status | |||
| Positive | 38 (79.2%) | 45 (60%) | 0.031 |
| Negative | 10 (20.8%) | 30 (40%) | |
| HER2 status | |||
| Positive | 3 (6.3%) | 6 (8.0%) | 0.745 |
| Negative | 45 (93.7%) | 69 (92.0%) | |
| Ki67 index | |||
| ≥14% | 32 (66.7%) | 50 (66.7%) | 1 |
| <14% | 16 (33.3%) | 25 (33.3%) | |
| PIK3CA † | |||
| Mutation | 11 (25%) | 4 (6.3%) | 0.006 |
| Wild type | 33 (75%) | 59 (93.7%) | |
| PIK3CA/AKT/KRAS* | |||
| Mutation | 16 (34.0%) | 7 (9.6%) | 0.001 |
| Wild type | 31 (66.0%) | 66 (90.4%) | |
| PTEN loss¶ | |||
| Yes | 16 (34.0%) | 29 (40.3%) | 0.493 |
| No | 31 (66.0%) | 43 (59.7%) | |
| PAM activation | |||
| Yes | 30 (62.5%) | 35 (46.7%) | 0.086 |
| No | 18 (37.5%) | 40 (53.3%) | |
†, successful analysis of PIK3CA sequencing, 44 cases vs. 63 cases
*, Mutation in any gene of PIK3CA, AKT, KRAS, 47 cases vs. 73 cases
¶, successful analysis of PTEN IHC, 47 cases vs. 72 cases.